Mode
Text Size
Log in / Sign up

Diplopia imposes substantial healthcare costs, exceeding national average in South KoreaDiplopia treatment costs three times more than the national average

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multidisciplinary, age- and etiology-based strategies to optimize diplopia care and reduce its economic burden.

This cross-sectional study analyzed claims data from insured individuals in South Korea with a diagnosis of diplopia, identified through diagnostic codes for diplopia and strabismus. The study aimed to quantify direct healthcare costs and utilization patterns associated with diplopia, and to explore demographic characteristics and age-specific prevalence. The cohort included 89,447 patients, representing a one-year prevalence of 0.17% among the insured population.

The study found that diplopia led to a substantial number of healthcare visits, with the majority occurring in ophthalmology, followed by neurology. The annual direct healthcare cost for diplopia was considerable, and the mean cost per visit or admission day was approximately three times the national average for outpatient visits or inpatient days. This indicates a higher resource intensity for managing diplopia compared to general healthcare encounters.

The authors highlight the need for age- and etiology-based, multidisciplinary strategies to optimize care and reduce healthcare costs. However, the study is based on claims data from a single year, and the cross-sectional design limits the ability to infer causality. The findings underscore the economic burden of diplopia and the importance of efficient care pathways.

Clinically, these results suggest that diplopia imposes a significant economic burden, and clinicians should be mindful of the potential for high healthcare utilization. Multidisciplinary collaboration may help streamline care and reduce costs.

Living with diplopia, or double vision, can be a significant burden. A large study of nearly 90,000 patients in South Korea looked at how much it actually costs to treat this condition and how often people seek help.

The data shows that while only about 0.17% of the insured population had diplopia, those who did required extensive care. Patients visited ophthalmology clinics over 70% of the time and neurology departments about 21% of the time. These visits are not cheap; the total annual cost for treating these patients reached nearly 60 billion won.

What makes this stand out is the cost per visit or admission day. It averaged around 241,077 won, which is more than three times the national average of 76,553 won. Because the study used data from a single year, it shows a snapshot of high costs and highlights why doctors need better, specialized plans to manage these cases effectively.

What this means for you:
Treating double vision costs significantly more than the national average for other medical visits.

Common questions

How much does it cost to treat double vision?

The study found that the annual direct healthcare cost for patients with diplopia reached 59.9 billion won. On a per-visit basis, the average cost was 241,077 won. This amount is more than three times higher than the national average of 76,553 won for other types of medical visits.

Which doctors usually treat patients with double vision?

The data shows that people with diplopia visit specialists frequently. About 70.2% of the total healthcare visits were to ophthalmology departments, while 21.3% of those visits were to neurology departments.

How common is double vision in the general population?

The study found that the one-year prevalence of diplopia was about 0.17%. This means that out of approximately 51.4 million insured individuals, about 89,447 people were identified with a diagnosis of diplopia or strabismus.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Diplopia is a disabling condition with diverse etiologies, but population-based studies on its healthcare utilization and healthcare costs are limited in South Korea. We conducted a nationwide cross-sectional study using all claims data submitted to the Korean Health Insurance Review and Assessment Service in 2023. Patients with diplopia were identified using diagnostic codes for diplopia and strabismus. Direct healthcare costs, healthcare utilization patterns, and demographic characteristics were analyzed, with subgroup analyses for ocular motor cranial nerve palsies. Among 51.4 million insured individuals in South Korea, 89,447 patients with diplopia were identified, corresponding to a one-year prevalence of 0.17%. Age-specific prevalence revealed a bimodal age distribution. A total of 248,431 diplopia-related healthcare visits were recorded, primarily managed in ophthalmology (70.2%) and neurology (21.3%). The annual direct healthcare cost attributable to diplopia was ₩59.9 billion, and the mean cost per visit or admission day was ₩241,077, approximately 3.1 times the national average insurance benefit cost per outpatient visit or inpatient day (₩76,553). This nationwide claims-based study demonstrates that diplopia is associated with substantially higher healthcare costs than the national average across all medical conditions, with marked heterogeneity by age and underlying etiology. These findings underscore the need for age- and etiology-based, multidisciplinary strategies for optimized care and reducing healthcare costs of diplopia.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.